• Home
  • Shine a Light
    • Watch
    • Listen
    • Read
  • Radiologists
  • Divisions
    • Abdominal
    • Breast
    • Cardiothoracic
    • Interventional Radiology
    • Molecular Imaging
    • Musculoskeletal
    • Neuroradiology
  • Activities
    • AI
    • AIEC
    • Business
    • Diversity/Equity/Inclusion
    • Education
    • Faculty Development
    • Innovation
    • IT
    • Primary Care rep.
    • Quality & Safety
    • Research
  • Hospitals
    • Toronto General Hospital
    • Toronto Western Hospital
    • Princess Margaret Cancer Centre
    • Women’s College Hospital
    • Sinai Health
  • About JDMI
Radiologists - UHN, WCH, Sinai Health, UofT Radiologists - UHN, WCH, Sinai Health, UofT Radiologists - UHN, WCH, Sinai Health, UofT Radiologists - UHN, WCH, Sinai Health, UofT Radiologists - UHN, WCH, Sinai Health, UofT
  • Home
  • Shine a Light
    • Watch
    • Listen
    • Read
  • Radiologists
  • Divisions
    • Abdominal
    • Breast
    • Cardiothoracic
    • Interventional Radiology
    • Molecular Imaging
    • Musculoskeletal
    • Neuroradiology
  • Activities
    • AI
    • AIEC
    • Business
    • Diversity/Equity/Inclusion
    • Education
    • Faculty Development
    • Innovation
    • IT
    • Primary Care rep.
    • Quality & Safety
    • Research
  • Hospitals
    • Toronto General Hospital
    • Toronto Western Hospital
    • Princess Margaret Cancer Centre
    • Women’s College Hospital
    • Sinai Health
  • About JDMI
Ur Metser

Ur Metser, MD, FRCPC

    • Site Director, Princess Margaret Cancer Centre
    • Division Head, Molecular Imaging

Dr. Ur Metser is the Division Head of Molecular Imaging at the Joint Department of Medical Imaging (UHN, Sinai Health and Women’s College Hospital), Site Director of Medical Imaging at the Princess Margaret Cancer Centre and holds the position of Professor of Radiology, Department of Medical Imaging at the University of Toronto. He is also the clinical lead in the core of Radiochemistry and Nanotechnology at the Techna Institute and chairs the Ontario Provincial Positron Emission Tomography Steering Committee at Cancer Care Ontario, responsible for the evidence-based introduction of PET in Ontario. He graduated from the Faculty of Medicine at the Technion (Haifa) and completed his residency training at the Sourasky Medical Center (affiliate of Tel Aviv University) and fellowship programs in abdominal imaging at the University of Toronto, and PET imaging at McMaster University.

After serving as staff radiologist at the Departments of Radiology and Nuclear Medicine in Tel-Aviv, he joined the Joint Department of Medical Imaging in the Divisions of Abdominal Imaging and Molecular Imaging. He is a fellow of the Royal College of Physicians (Canada) and an active member in multiple international professional societies including the Radiological Society of North America, American Roentgen Ray Society, and Society of Nuclear Medicine, amongst others. Dr. Metser has published over 100 manuscripts in peer-reviewed journals, as well as multiple review articles, book chapters and practice guidelines. He is also a reviewer for a few of the field’s leading medical journals and is on the editorial board of Journal of Computed Axial Tomography.

His main clinical and research interests focus on novel molecular imaging probes, theranostics, hybrid imaging (PET/CT and PET/MR) for tumour detection, characterization and assessment of response to therapy with functional imaging.

View the Molecular Division

Recent Publications

  • Prognostic Value of Sarcopenia and Metabolic Parameters of 18F-FDG-PET/CT in Patients with Advanced Gastroesophageal Cancer

    We investigated the prognostic value of sarcopenia measurements and metabolic parameters of primary tumors derived from ^(18)F-FDG-PET/CT among […]

  • The role of [18F]-DCFPyL PET/MRI radiomics for pathological grade group prediction in prostate cancer

    CONCLUSION: The combined [^(18)F]-DCFPyL PET/MRI radiomic model was the best-performing model and outperformed the clinical model for pathological […]

  • Standardized classification schemes in reporting oncologic PET/CT

    The imaging report is essential for the communication between physicians in patient care. The information it contains must be clear, concise with […]

  • 18F-FDG PET/MRI in Detection of Pulmonary Malignancies: A Systematic Review and Meta-Analysis

    Background There have been conflicting results regarding fluorine 18-labeled fluorodeoxyglucose (^(18)F-FDG) PET/MRI diagnostic performance in lung […]

  • CT Radiomics and Whole Genome Sequencing in Patients with Pancreatic Ductal Adenocarcinoma: Predictive Radiogenomics Modeling

    We investigate whether computed tomography (CT) derived radiomics may correlate with driver gene mutations in patients with pancreatic ductal […]

  • Prognostic Value of [18F]-FDG PET/CT Radiomics Combined with Sarcopenia Status among Patients with Advanced Gastroesophageal Cancer

    We investigated, whether 18[18F]-FDG PET/CT-derived radiomics combined with sarcopenia measurements improves survival prognostication among patients […]

  • Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma

    CONCLUSION: Our study demonstrated that PET/CT-based radiomic features may improve survival prognostication among NPC patients when combined with […]

  • Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial

    BACKGROUND: Detection of skeletal metastases in patients with prostate cancer or breast cancer remains a major clinical challenge. We aimed to […]

  • 18F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study

    CONCLUSION: Although ^(18)F-DCFPyL has higher specificity than CT in detecting advanced HGSOC tumor sites, it detects less disease sites than CT, […]

  • A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer

    CONCLUSIONS: Metformin decreased cervical tumor hypoxia in this trial that selected for patients with hypoxic tumor. See related commentary by Lyng […]

  • Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer

    CONCLUSIONS: Half of patients treated with MDT for molecularly defined-only oligorecurrent prostate cancer exhibited a biochemical response. This […]

  • Nasopharyngeal Carcinoma Radiomic Evaluation with Serial PET/CT: Exploring Features Predictive of Survival in Patients with Long-Term Follow-Up

    CONCLUSIONS: This study with long-term follow up data on NPC suggests that mainly PET-derived radiomic features are predictive for OS but not PFS in […]

  • Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis

    CONCLUSION: This meta-analysis showed an overall high diagnostic performance for [^(18)F]-FDG PET/MR in detecting CRC lesions/metastases. Thus, this […]

  • Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer

    Background Data regarding 2-(3-{1-carboxy-5-[(6-[^(18)F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (^(18)F-DCFPyL) PET in […]

  • Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis

    Background There is limited consensus regarding the relative diagnostic performance of cardiac MRI and fluorodeoxyglucose (FDG) PET for cardiac […]

  • Combined 18 F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer

    CONCLUSIONS: PET and CT radiomics derived from combined PET/CT integrated with clinicopathological parameters and sarcopenia measurement might […]

  • The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis

    CONCLUSION: In conclusion, PSMA PET is positive in more than 2/3 of men with BCR and impacts patient management in more than half of the men. BRFS […]

  • Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume

    Pretransplant Deauville score (DS) is an imaging biomarker used for risk stratification in relapsed/refractory classical Hodgkin lymphoma (cHL). […]

  • Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation

    CONCLUSION: Detectable plasma HPV DNA at end of CRT predates the clinical diagnosis of metastases and is associated with inferior progression-free […]

  • Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial

    Background The high positivity rate of prostate-specific membrane antigen (PSMA) PET in the setting of biochemical failure (BCF), even when […]

  • The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients

    CONCLUSIONS: Thresholds of SUVmax and SUVratio identified a significant proportion of patients who did not develop adrenal metastasis. In oncology […]

  • Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis

    CONCLUSIONS: Combined cardiac FDG-PET/MRI with T1/T2 mapping provides complementary diagnostic information and predicts MACE in patients with […]

  • The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors

    CONCLUSION: In patients with SSTR-RADS 5 PM-NETs treated with 177Lu-DOTATATE, there was similar response to therapy for all lesions with […]

  • 68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement

    CONCLUSION: This study showed a substantial interobserver agreement in the overall interpretation and detecting locoregional and distant involvement […]

  • Placenta increta mimicking placental site trophoblastic tumor

    No abstract

  • Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer

    CONCLUSIONS: Our developed radiomics signature demonstrated modest discriminative accuracy; however, these results may have been influenced by small […]

  • Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease

    CONCLUSIONS: In our series of salvage dissection for PSMA-PET-detected nodal oligometastases, approximately a third achieved PSA

  • Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma

    CONCLUSIONS: The set of radiomic signatures was found to have limited ability to discriminate nivolumab responders from non-responders. The use of […]

  • Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer

    CONCLUSION: Combining the patients' imaging-derived sarcopenic status with standard clinical data, but not metabolic parameters, offered an overall […]

  • 18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center

    CONCLUSION: ^(18)F-DCFPyL PET was positive in >90% of patients with biochemical failure. For those with limited recurrence, PSMA PET-directed […]

University Medical Imaging Toronto University of Toronto | created by Techna Institute, UHN - 2023